Ibrutinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ibrutinib: From B-Cell Malignancies to Polyclonal Hypergammaglobulinemia
One-Sentence Summary
Ibrutinib is an oral BTK inhibitor, originally used for B-cell cancers such as mantle cell lymphoma, Waldenström macroglobulinemia and acute lymphoblastic leukemia, and for graft versus host disease. The TxGNN model predicts it may be effective for polyclonal hypergammaglobulinemia, but currently there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | B-cell malignancies and graft versus host disease (Singapore label text is not available; this is taken from the knowledge-graph indication list, which includes mantle cell lymphoma, Waldenström macroglobulinemia, B-cell neoplasm and acute lymphoblastic leukemia) |
| Predicted New Indication | Polyclonal hypergammaglobulinemia |
| TxGNN Prediction Score | 91.75% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, ibrutinib inhibits Bruton's tyrosine kinase (BTK), which is central to B-cell receptor signaling, B-cell survival and antibody production.
Polyclonal hypergammaglobulinemia is a raised level of immunoglobulins produced by many B-cell clones. Because BTK drives antibody-producing B-cell activity, reduced BTK signaling could plausibly lower immunoglobulin levels.
This reasoning has an important limit. Low immunoglobulin levels (hypogammaglobulinemia) are a known effect of BTK inhibition, not a therapeutic goal. Polyclonal hypergammaglobulinemia is also usually a laboratory finding that reflects an underlying condition, so it is not a typical treatment target. No clinical or published evidence in the compiled data supports this use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN16221P | IMBRUVICA Film-Coated Tablets 560 mg | Tablet, film coated |
| SIN16218P | IMBRUVICA Film-Coated Tablets 140 mg | Tablet, film coated |
| SIN16219P | IMBRUVICA Film-Coated Tablets 280 mg | Tablet, film coated |
| SIN16220P | IMBRUVICA Film-Coated Tablets 420 mg | Tablet, film coated |
All four licences are valid single-ingredient oral products. Approved indication text is not available in the compiled data.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BTK inhibitor), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Cardiac status (atrial fibrillation, blood pressure) and bleeding risk are the main concerns noted for this drug; for other parameters, please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interacting drugs. The main ones include:
- Major: aprepitant, acetylsalicylic acid (aspirin), clarithromycin, cobicistat, deferasirox
- Moderate: dexamethasone, cimetidine, miconazole, clotrimazole, rifaximin, loperamide, and the DPP-4 inhibitors sitagliptin, saxagliptin and linagliptin
- Other concerns: Many of the interactions involve CYP3A4. Cardiac toxicity (atrial fibrillation, hypertension) and bleeding risk are also recognised concerns for ibrutinib.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN score (91.75%). There are no clinical trials or publications, and the main expected effect of BTK inhibition on immunoglobulins (lowering them) is a side effect, not a treatment benefit. The condition is also not a typical stand-alone treatment target.
To proceed, the following is needed:
- Clinical or preclinical evidence that ibrutinib benefits patients with polyclonal hypergammaglobulinemia
- Clarification of which underlying disease would be treated, since this is generally a secondary finding
- Detailed mechanism of action data
- Singapore package insert warnings and contraindications for a full safety review
- A DDI management plan (CYP3A4) and a cardiac and bleeding monitoring plan, if development continues
Other predictions with stronger support: Among the other predictions for ibrutinib, marginal zone lymphoma (L1, including the Phase 3 SELENE trial) and neoplasm of mature B-cells (L1) have far stronger evidence. Both overlap closely with existing indications, so they are largely confirmatory rather than new repurposing. They may be better candidates for further evaluation than polyclonal hypergammaglobulinemia.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.